Inex Medicaments Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-07-2024
- Paid Up Capital ₹ 0.50 M
as on 18-07-2024
- Company Age 15 Year, 6 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.00 M
as on 18-07-2024
- Revenue 4.75%
(FY 2023)
- Profit 3.08%
(FY 2023)
- Ebitda -25.03%
(FY 2023)
- Net Worth 15.14%
(FY 2023)
- Total Assets 0.42%
(FY 2023)
About Inex Medicaments
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.50 Cr.
Gopalakrishnan Srinivasan and Ajithkumar serve as directors at the Company.
- CIN/LLPIN
U51909TN2009PTC073452
- Company No.
073452
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Inex Medicaments Private Limited offer?
Inex Medicaments Private Limited offers a wide range of products and services, including Skin Care, Bath Essentials, Facewash, Health Conditions, Heart Care.
Who are the key members and board of directors at Inex Medicaments?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopalakrishnan Srinivasan  | Managing Director | 06-Nov-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ajithkumar | Director | 06-Nov-2009 | Current |
Financial Performance and Corporate Structure Insights of Inex Medicaments.
Inex Medicaments Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.75% increase. The company also saw a slight improvement in profitability, with a 3.08% increase in profit. The company's net worth Soared by an impressive increase of 15.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Inex Medicaments?
In 2023, Inex Medicaments had a promoter holding of 85.00% and a public holding of 15.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 13 May 2016 | ₹1.50 Cr | Open |
How Many Employees Work at Inex Medicaments?
Unlock and access historical data on people associated with Inex Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inex Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inex Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
